Martinsried/Munich (Germany), Waltham, Mass. and Princeton, N.J., December 15, 2005 – GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; NASDAQ: GPCB) today announced that the Company has begun the rolling submission of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for satraplatin in combination with prednisone as a second-line chemotherapy treatment for patients with hormone-refractory prostate cancer (HRPC). To begin the rolling NDA process, the Company has submitted to the FDA the chemistry, manufacturing and controls – or CMC – section of the NDA filing.
